周致聪Chau, Charles

合伙人

香港 + 852.3189.7268

周致聪律师提供有关香港、中国大陆和亚太区域的并购、资本市场(包括上市和公开发行)、证券监管合规、合资经营和其他商业交易方面的法律咨询服务。他在银行和金融服务、医疗保健、生物技术、零售、房地产和制造业等众多行业领域拥有丰富的法律服务经验。周律师曾代表客户处理100余起公私营公司收购、合资经营、融资和IPO前投资交易。他还曾代表多家中国公司处理其在美国的境外收购事宜。

在2017年加入众达之前,周律师曾代表中国北车股份有限公司处理其与中国南车股份有限公司之间价值260亿美元的合并交易,这是首次由两家同时在香港和上海上市的公司之间进行合并。此外,他还曾参与处理众多首次公开发行及证券配售交易,包括国药控股、中国北车、国电科技环保集团的首次公开发行以及中信银行的A+H股供股发行。

周律师在多个公共组织任职,包括人事登记裁判处审裁员以及香港总商会法律委员会和卓青社委员。

经验

  • China Post Group Limited invests $128 million in Ule Holdings LimitedJones Day advised China Post Group Limited with its $128 million investment in Ule Holdings Limited through Telpo Philatelic Company Limited ("Telpo"), a subsidiary of China Post.
  • GenScript Biotech Corporation completes US$402 million follow-on offering by Legend Biotech CorporationJones Day represented GenScript Biotech Corporation in connection with a US$402 million follow-on offering by its Nasdaq-subsidiary Legend Biotech Corporation (NASDAQ: LEGN).
  • Hong Kong and China Power Holdings invests in Luquos Holding Limited (Luquos Cayman) seed roundJones Day represented Hong Kong and China Power Holdings Company Limited in the series seed round of financing of Luquos Holding Limited (Luquos Cayman).
  • GenScript Bio's non-wholly-owned subsidiary Probio Technology Limited raises $37 million in Series B financingJones Day represented GenScript Biotech Corporation (HK Stock Code: 1548) ("GenScript Biotech") in the $37 million Series B financing of non-wholly-owned subsidiary Probio Technology Limited ("Probio Cayman"), led by Zhenjiang High-tech Venture Capital (HK) Limited.
  • Albaugh acquires RotamJones Day advised Albaugh, LLC in the $197.5 acquisition of Rotam Global AgroSciences Limited, a company headquartered in Hong Kong and publicly listed on the Taiwan Stock Exchange.
  • LeaderMed Health Group expands pipeline with Aqualung licenseJones Day represented LeaderMed Health Group Limited in subscription of a convertible note and an exclusive license agreement with Aqualung Therapeutics Corporation ("Aqualung") to develop, manufacture, and commercialize Aqualung's clinical stage antibody product ALT-100 in eight Asian territories, including Greater China.
  • Samson Paper Holdings Limited completes US$385 million cross-border restructuringJones Day advised Samson Paper Holdings Limited (the "Company"), a Bermuda incorporated company listed on the Main Board of the Stock Exchange of Hong Kong in connection with its US$385 million Bermuda/Mainland China/Hong Kong cross-border restructuring deal (the "Restructuring").
  • GenScript Biotech Corporation completes US$344.6 million follow-on offering by Legend Biotech CorporationJones Day represented GenScript Biotech Corporation in connection with its US$344.6 million follow-on offering by its NASDAQ-subsidiary Legend Biotech Corporation.
  • LeaderMed Health Group Limited enters into joint venture and licensing agreement with OPKO Health to develop and commercialize innovative drugs in Asian countriesJones Day represented LeaderMed Health Group Limited in the formation of a joint venture and exclusive license agreement with OPKO Health, Inc. ("OPKO") to develop, manufacture, and commercialize two of OPKO's clinical stage, long-acting drug products, Oxyntomodulin and Factor VIIa-CTP, in Greater China and eight other Asian territories.
  • GenScript Biotech and its subsidiaries Legend Biotech and ProBio Cayman complete US$1.07 billion investment by Hillhouse CapitalJones Day represented GenScript Biotech Corporation (“GenScript Biotech”), its controlling shareholder GenScript Corporation, and its two subsidiaries Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”) and Probio Technology Limited (“Probio Cayman”) in connection with a US$1.07 billion investment by Hillhouse Capital.
  • EagleTree Capital acquires IntegreonJones Day advised EagleTree Capital in connection with the acquisition and financing of Integreon, a leading global managed services provider, from NewQuest Capital Partners.
  • Solmax acquires TenCate GeosyntheticsJones Day advised Groupe Solmax Inc. (Solmax), the global leader in the production of high-quality polyethylene geomembranes for industrial and environmental applications, and its shareholders (including institutional investors Caisse de dépot et placement du Québec and Fonds de Solidarité FTQ), in connection with Solmax’s acquisition of TenCate Geosynthetics Holding B.V., a global provider of geosynthetics and industrial fabrics, from Dutch conglomerate Koninklijke Ten Cate (Royal Ten Cate, the Netherlands), and advised on the related senior secured financing to support the acquisition.
  • ETS acquires VericantJones Day advised Educational Testing Service in its acquisition of Vericant, a provider of secure, verified in person interviews and Spoken English Evaluations worldwide.
  • Best Courage Global participates in Series A financing round of Aland Health Holding Ltd.Jones Day represented Best Courage Global Limited in connection with the Series A financing round of Aland Health Holding Ltd., a designer, manufacturer, seller and distributor of vitamins and other health and nutrition supplements and a provider of nutrition management solutions.
  • Successful Lotus Limited makes HK$40 million investment in Ganglong China Property Group LimitedJones Day represented Successful Lotus Limited in making a cornerstone investment in Ganglong China Property Group Limited, whose principal business is the development and sales of properties predominantly for residential use mixed with accompanying ancillary facilities, by way of subscription of shares for HK$40 million.
  • GenScript Biotech Corporation completes US$423.8 million IPO and spin-off of its subsidiary Legend Biotech Corporation; and US$24 million purchase of Ordinary Shares of Legend BiotechJones Day acted as the U.S. and Hong Kong legal advisors of GenScript Biotech Corporation (“GenScript Biotech”) in relation to its (a) approximately US$423.8 million initial public offering of 18,425,000 American Depositary Shares and spin-off listing of its subsidiary Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”) on the Nasdaq Global Select Market and (b) approximately US$24 million purchase of Ordinary Shares of Legend Biotech in a concurrent private placement of Legend Biotech.
  • Successful Lotus Limited makes HK$21 million investment in Ye Xing Group Holdings LimitedJones Day represented Successful Lotus Limited in making a cornerstone investment in Ye Xing Group Holdings Limited, whose principal business is the provision of property management and related services for residential and non-residential properties in China, by way of subscription of shares for HK$21 million.
  • GeneoDx invests in PathoFinderJones Day represented Shanghai GeneoDx Biotech Company Limited, a subsidiary of Sinopharm Group, a leading pharmaceutical company in China, in connection with its investment in PathoFinder Holding B.V. (PFH), which is engaging in molecular diagnostics for the detection of pathogens causing an infectious disease in the Netherlands, by way of purchasing a majority stake in PFH.
  • PETRONAS Chemicals acquires Da Vinci Group B.V. for €163 millionJones Day advised PETRONAS Chemicals Group Berhad (PCG) in its acquisition of a 100% stake in Da Vinci Group B.V. from its shareholders including funds managed by Bencis Capital Partners for €163 million.
  • Sino Power Resources completes subscription of new shares in FDG Electric Vehicles LimitedJones Day assisted Sino Power Resources Inc., a subsidiary of China Orient Asset Management (International) Holding Limited, in connection with its subscription of new shares in FDG Electric Vehicles Limited, a vertically-integrated electric vehicle manufacturer.
  • 以下案例为Charles在加入众达之前的工作经历。

    在位于广州的恒大地产集团有限公司价值6亿美元的“先旧后新”配股过程中,为作为配售代理的里昂证券、瑞士信贷、海通国际和杰富瑞提供代理服务。

    代表香港格力电器销售有限公司在红星美凯龙进行香港证券交易所首次公开发行过程中对其进行1亿美元的基石投资。

    代表香港格力电器销售有限公司在大连万达商业地产股份有限公司进行香港证券交易所首次公开发行过程中对其进行2亿美元的基石投资。此次首次公开发行是2014年最受瞩目的资本市场交易之一。

    在生命科学研究及应用服务公司金斯瑞生物科技有限公司进行价值5.24亿港币的港交所首次公开发行过程中为独家保荐人海通国际证券集团有限公司和承销人海通国际证券集团有限公司、摩根大通证券(亚太)有限公司、摩根大通证券股份有限公司和兴业金融证券有限公司提供代理服务。

    代表中国宏泰产业市镇发展有限公司进行价值1.32亿美元的港交所首次公开发行。中国宏泰是一家主要提供中国大型工业城镇规划、开发和运营服务的领先提供商,其服务对象主要是土地面积超过1,000万平米的工业城镇。

    在国药控股募集40亿港币(约合5.15亿美元)的新H股配售过程中为配售代理中国国际金融股份有限公司(“中金”)、瑞士联合银行和摩根士丹利提供代理服务。

    在中信银行进行价值40亿美元的A+H股供股发行过程中为联合承销人中国国际金融股份有限公司(“中金”)和中信证券提供代理服务。就总资产而言,中国中信集团是中国第七大出借人。

    在中国最大的药品及医疗保健产品分销商国药控股股份有限公司进行价值4.425亿美元的H股配售过程中为配售代理中国国际金融公司、瑞士联合银行和摩根士丹利提供代理服务。

    在远洋地产控股有限公司通过股东中远国际控股有限公司进行价值6.84亿美元的配股过程中为配售代理中银国际亚洲有限公司和瑞士联合银行提供代理服务。

    代表泓琳科技集团有限公司在香港股票交易所进行的6500万美元首次公开发行。Piper Jaffray Asia Securities Limited是本次交易的唯一的主承销人。

    代表邓普顿新兴市场资金III, LDC,中化欧洲资本有限公司,建银国际资产管理有限公司拟以及新世界策略投资有限公司对十方控股有限公司的3500万美元的投资项目。十方控股是在福建设立的一家电子与印刷媒体的内容供应商。

    代表中国智能交通系统(控股)有限公司上市前融资的各环节,并介绍Baring,Investor AB,招商局集团,Temasek Capital (Private) Limited,通用资本,英特尔投资公司,瑞穗银行以及新创建集团作为其股东。

    代表中国国际金融股份有限公司、瑞士银行集团、摩根士丹利亚洲有限公司、德意志银行以及花旗环球金融亚洲有限公司在内的承销商集团,承销国药控股股份有限公司在香港首次公开发行的11亿美元股票。国药控股是中国最大的医药品经销商,并由国有企业中国医药集团总公司经营。此次首次公开发行项目被《亚洲金融》(Finance Asia)评为“年度最佳IPO交易”,并在《国际金融亚洲评论》(IFR Asia) 2009 年荣誉榜中被评为 “最佳股本交易”。

    代表美林远东有限公司和中银国际亚洲有限公司在内的承销商集团,承销华南城控股有限公司在香港股票交易所首次公开发行的4亿美元股票。华南城控股有限公司是中国国内大型物流及商贸中心开发与运营的领航者。

    代表中信证券国际、瑞士联合银行集团、摩根大通证券以及麦格理资本在内的承销商集团,承销中国忠旺控股有限公司在香港股票交易所进行首次公开发行的13.8亿美元股票及其上市股份。

    代表中银国际亚洲有限公司、香港上海汇丰银行有限公司、摩根士丹利亚洲有限公司以及瑞士联合银行在内的承销商商集团,承销人和商业控股有限公司在香港股票交易所首次公开发行的4.35亿美元股票及上市股份。人和商业控股有限公司是中国领先的地下商场开发者及运营商。

    代表作为配售代理的嘉诚亚洲有限公司配售浙江玻璃股份有限公司H股3.88亿港元(占该公司已发行股本的8.9%)。

    代表知名百货公司运营商茂业国际控股有限公司在香港股票所进行的3.43亿美元的首次公开发行。

    代表金山软件有限公司在香港股票交易所进行的1.15亿美元首次公开发行上市。金山软件有限公司在软件开发、软件经销、软件服务提供方面居于中国国内领先地位。

    代表华润电力额外配售6.264亿美元的股份,此次交易共增加约2亿股份(约合46亿港元)。摩根士丹利国际有限公司以及花旗环球金融亚洲有限公司为本次配售交易的联合配售代理。